Table 1.
Metastatic melanoma patient cohort.
| Primary Tumor | N = 10 (100%) |
|---|---|
| Breslow thickness: range+SEM | 4.44 (1.0–9.25) |
| <1.0 | 1 (10) |
| 1.1–2.0 | 2 (20) |
| 2.1–4.0 | 2 (20) |
| >4.1 | 5 (50) |
| Histological types | |
| SSM | 3 (30) |
| NM | 2 (20) |
| LMM | 1 (10) |
| unclassified | 4 (40) |
| Anatomical location | |
| trunk | 2 (20) |
| head and neck | 2 (20) |
| extremities | 6 (60) |
| Mutational status | |
| BRAFV600K/E | 6 (60) |
| NRASQ61L/R | 3 (30) |
| BRAF/NRAS/KIT wild type | 1 (10) |
| Gender | |
| male | 6 (60) |
| female | 4 (40) |
| Age (years) | 47.6 + 18.1 |
| Overall survival (months): range + SD | 69.3 + 39.6 |
| Treatment | |
| IFN2α | 7 (70) |
| BRAFi | 3 (30) |
| DTIC | 2 (20) |
| cisplatinum | 2 (20) |
| Metastasis | N = 28 (100%) |
| brain | 10 (36) |
| liver | 9 (32) |
| lung | 9 (32) |
Abbreviations: BRAFi, BRAF inhibitor; DTIC, Dacarbazine; LMM, lentiginous melanoma; NM, nodular melanoma; SSM, superficially spreading melanoma.